Menu
Not yet recruiting NCT06818903

Misoprostol in Missed Abortion

Observational Abortion; Attempted

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Misopristol, Foley catheter.
Who it may be relevant to
Registry conditions: Abortion; Attempted. Basic parameters: 18 years — 40 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Misoprostol Versus Intracervical Foley's Catheter for Termination of Second Trimester Abortion

Overview

In this study we compare between the effectiveness of combined Foley's catheter with Misoprostol and intracervical Foley's catheter alone for termination of second trimester abortion.

Detailed description

Termination of pregnancy (TOP) is defined as elective expulsion or extraction of products of conception from uterus instead of spontaneous onset of process irrespectable of duration of pregnancy. Worldwide mid-trimester abortion constitutes 10-15% of all induced abortions but responsible for two-thirds of all major complications Despite the recent advances in prenatal diagnosis in first trimester. Termination of pregnancy in second trimester due to foetal abnormalities and intrauterine foetal death still accounts for large number of abortions, and has increased the demand for rapid termination of pregnancy. In intrauterine fetal death in 2nd trimester, expulsion may take several weeks. This is associated with psychological trauma, coagulopathy and intrauterine infection. Among various methods of second trimester termination, evacuation and curettage induces risk of bleeding, infection, uterine perforation and cervical trauma. The introduction of misoprostol , a synthetic prostaglandin E1 analogue (PGE1) has become an important for cervical ripening and uterotonic action. It is economic, stable at room temperature and is associated with few side effects such as fever, vomiting and diarrhea. There is still debate about doses, routes and regimes of PGE1 for termination of pregnancy during 2nd trimester. It is active orally but more effective and better tolerated when administrated vaginally and has fewer side effects. Vaginal route is preferred in first and second trimester. The use of Foley's catheter has been recommended in many developing countries. The reports from different countries have mentioned excellent results with the use of Foley's catheter either alone or in combination with prostaglandins. The scope of our study: is to compare the use of Foley's catheter combination with Misoprostol versus Foley's catheter alone for pre induction cervical ripening and induction of second trimester abortion.

Interventions

  • Drug Misopristol
    Foley catheter with Misopristol local application
  • Device Foley catheter
    Foley catheter alone

Primary outcome measures

  • Interval time [Time frame: periprocedurally]

Eligibility criteria

Inclusion criteria

  • Women aged between 18 - 40 years of age with mid-trimester fetal death inutero.
  • Singleton pregnancies from 18-24 weeks.
  • women with unfavourable cervix (Bishop Score < 5) at the time of recruitment.
  • Previous one CS and non-previous CS pregnant women.

Exclusion criteria

  • • Previous 2 CS or more.
  • Medical contraindications for prostaglandin therapy (allergy to prostaglandins or severe asthma).
  • co-morbidities like severe anemia (Hb < 7g/dl), hypertension, diabetes, or coagulopathy .
  • Women with excessive vaginal discharge or rupture of membrane.
  • Women having any complication in previous caesarean like endometritis, reopening, scar dehiscence etc.
  • Active genital infection e. g. active genital Herpes simplex infection.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06818903 · A456743

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗